Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL – Get Free Report) have been given an average rating of “Moderate Buy” ...

Fintel reports that on January 10, 2025, Needham upgraded their outlook for Collegium Pharmaceutical (NasdaqGS:COLL) from Hold to Buy. Analyst Price Forecast Suggests 29.26% Upside As of December 23, ...

HC Wainwright reiterated their buy rating on shares of Collegium Pharmaceutical (NASDAQ:COLL – Free Report) in a research report report published on Friday,Benzinga reports. They currently have a $50.

Check the time stamp on this data. Updated AI-Generated Signals for Collegium Pharmaceutical Inc. (COLL) available here: COLL ...

Collegium Pharmaceutical announced its 2025 financial guidance, projecting product revenues between $735 and $750 million, with a focus on Jornay PM expected to exceed $135 million in net revenue.

In a report released today, Serge Belanger from Needham upgraded Collegium Pharmaceutical (COLL – Research Report) to a Buy, with a price ...

Collegium Pharmaceutical forecasts 2025 product revenues of $735-$750 million, with adjusted EBITDA of $435-$450 million. Collegium Pharmaceutical, Inc. has provided its financial guidance for ...

In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on Collegium Pharmaceutical (COLL – Research Report), with ...

STOUGHTON, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced its 2025 full-year financial guidance and provided a business update.

Jan. 08, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced its 2025 full-year financial guidance and provided a business update. "In 2024, we executed on our ...

Collegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients ...